Table 1.
Temporal sensitivity and overall specificity of the principal SARS-CoV-2 antibody assays as reported by the manufacturers
| Company | Commercial name | Antibodies analyzed* | Technology | Sensitivity | Specificity | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | ≥ 21 days | |||||
| Abbott Diagnostics | SARS-CoV-2 IgG | IgG (N) | Chemiluminescence | 0% | 25% | 83.4% | 100% | 99.6% | |||||||||||||||||
| Diasorin | Liaison SARS-CoV-2 IgG | IgG (S1, S2) | Chemiluminescence | 25% | 95% | 97.4% | 98.5% | ||||||||||||||||||
| Eurolmmun | Anti-SARS-CoV-2 IgG | IgG (S1) | ELISA | 30.3% | 75% | 93.8% | 99.6% | ||||||||||||||||||
| Anti-SARS-CoV-2 IgA | IgA (S1) | ELISA | 51.5% | 91.7% | 100% | 92.4% | |||||||||||||||||||
| Roche Diagnostics | Elecsys Anti-Sars-CoV-2 | Total Ig (N) | Electro-chemiluminescence | 65.5% | 88.1% | 100% | 99.8% | ||||||||||||||||||
| Vircell | COVID-19 VIRCLIA IgG | IgG (N, S) | Chemiluminescence | 37% | 74% | NA | 92% | 99% | |||||||||||||||||
| COVID-19 VIRCLIA IgA+IgM | IgA, IgM (N, S) | Chemiluminescence | 50% | 78% | NA | 87% | 99% | ||||||||||||||||||
*N, Ig against nucleocapsid protein; S1 and S2, spike proteins 1 and 2, respectively. NA, not available